November 16, 2021
Life Sciences
  • The Biden administration is withdrawing a Trump-era policy that limited the FDA’s review process of certain lab tests, including some COVID-19 tests. Under the policy, the agency did not require premarket reviews of laboratory-developed tests, even in situations in which they had poor performance. The rollback of this policy is intended to increase public access to more reliable tests, which experts say are still a cornerstone of pandemic protection. (Article here)